BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says

By Katryna Perera · February 24, 2023, 10:15 PM EST

California-based BioMarin Pharmaceutical Inc. and two of its executives face an investor suit accusing them of failing to disclose troubles facing its "revolutionary" Hemophilia A gene therapy Valrox during its testing...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Alger Capital Appreciation Fund et al v. Biomarin Pharmaceutical Inc et al

Case Number

3:23-cv-00826

Court

California Northern

Nature of Suit

Other Fraud

Date Filed

February 23, 2023